SecBot SecBot
Biotech Drug Report Generated Oct 29, 2026

GARDASIL

MRK·Merck & Co., Inc.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already approved and commercially marketed since 2014 (GARDASIL 9).
Why 4/10
GARDASIL 9 is already approved and commercially marketed with no pending PDUFA, AdComm, or pivotal readout in the next ~12 months. The next hard catalyst would be the confirmatory trial readout for the oropharyngeal cancer indication, but no specific date has been announced. As an approved product at a large diversified pharma company, the binary-catalyst-driven share-price move potential for this single drug is limited.
Actionable Insight NEUTRAL

Watch for the confirmatory trial readout for the oropharyngeal/head-and-neck cancer indication (no date announced), which could convert the accelerated approval to full approval or, in a negative scenario, narrow the label. Also monitor quarterly Gardasil sales trends for evidence of a China demand recovery or further deterioration, and the progress of Merck's single-dose regimen trials, which could expand the addressable market if successful.

Price Chart

Loading chart...

Executive Summary

GARDASIL / GARDASIL 9 is Merck's blockbuster HPV vaccine, approved since 2014 and the dominant product in its category. It generated $5.2 billion in 2025 sales (down 39% from 2024) as demand collapsed in China, Merck's largest market for the vaccine. The company halted China shipments in early 2026 and withdrew its $11 billion peak-sales target. Q3 2026 sales of $1.995 billion beat analyst expectations, suggesting some stabilization. A multi-year product-liability MDL is effectively resolved after Merck won summary judgment and settled ~200 remaining cases for ~$50 million in June 2026. The drug faces no imminent binary regulatory catalyst, making it a steady commercial contributor to Merck rather than a near-term share-price swing driver.

How It Works

GARDASIL 9 is a vaccine that trains the immune system to recognize and fight nine strains of human papillomavirus (HPV), a sexually transmitted virus that causes virtually all cervical cancers and a large share of oropharyngeal, anal, vulvar, vaginal, and penile cancers. It contains non-infectious virus-like particles that trigger antibody production without causing infection.

Trial Status

GARDASIL 9 was initially FDA-approved in 2014 and has since received expanded indications including oropharyngeal and head-and-neck cancer prevention (accelerated approval). Merck presented 14- and 18-year follow-up data at the EUROGIN 2026 congress confirming long-term efficacy. A post-marketing confirmatory trial for the oropharyngeal cancer indication is ongoing. Merck has also announced plans for two Phase 3 trials evaluating a single-dose regimen of GARDASIL 9.

The Two-Sided Case

▲ Bull Case4
GARDASIL 9 is the dominant HPV vaccine in the U.S. and most developed markets, with a strong efficacy profile covering 9 HPV strains responsible for ~90% of HPV-related cancers.
Q3 2026 Gardasil sales of $1.995 billion beat analyst expectations of $1.76 billion, signaling a potential recovery from the 2025 China-driven slump.
The expanded FDA indication for oropharyngeal and head-and-neck cancer prevention opens a large adult male market segment, and long-term efficacy data (14-18 years) reinforce the product's durability.
The Gardasil MDL litigation is effectively resolved: Merck won summary judgment in March 2025, the Supreme Court declined review in March 2026, and a ~$50M settlement in June 2026 resolved ~200 remaining cases, removing a legal overhang.
▼ Bear Case5
Gardasil sales fell 39% in full-year 2025 to $5.2 billion from $8.6 billion in 2024, driven by collapsing demand in China. Merck halted China shipments in early 2026 and restructured its distribution deal with Zhifei.
Merck's 2026 outlook explicitly excluded any Gardasil shipments to China, and the company withdrew its prior $11 billion peak-sales target for the vaccine.
The oropharyngeal cancer indication is approved under accelerated approval and requires a confirmatory trial; failure to verify clinical benefit could narrow the label.
Competition is emerging from lower-cost HPV vaccines (GSK's Cervarix, China's Cecolin and Walrinvax), and WHO single-dose recommendations could pressure pricing and volumes.
Merck's quant composite score is -18 (neutral/weak), with deteriorating 30-day estimate revisions and an RSI of 43.5, suggesting near-term technical softness.

Upcoming Catalysts

  • Ongoing confirmatory trial for oropharyngeal/head-and-neck cancer accelerated approval (no specific readout date announced)
  • Single-dose regimen Phase 3 trials (enrollment expected to begin; no specific readout date)
  • Quarterly sales updates as part of Merck earnings (next: Q4 2026 / full-year 2026, early Feb 2027)

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Merck & Co., Inc. 8-K MRK ·Originating report

Sources · 10

Hover a chip for the title
1 merck.com2 cnbc.com3 squawknews.com4 merck.com5 merck.com6 fiercepharma.com7 insurancejournal.com8 settlementinsight.com9 fda.gov10 merck.com